Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27071768)

Published in Adv Ther on April 12, 2016

Authors

Kathrin Herrmann1, Steven C Brunell1, Yan Li1, Ming Zhou2, David G Maggs1

Author Affiliations

1: Bristol-Myers Squibb/AstraZeneca, San Diego, CA, USA.
2: Bristol-Myers Squibb, Pennington, NJ, USA. ming.zhou@bms.com.

Associated clinical trials:

Epidemiology of Diabetes Interventions and Complications (EDIC) | NCT00360893

Diabetes Control and Complications Trial (DCCT) | NCT00360815

Articles cited by this

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56

Pathogenesis of NIDDM. A balanced overview. Diabetes Care (1992) 6.56

Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med (2009) 4.28

Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA (1998) 3.48

The T1D Exchange clinic registry. J Clin Endocrinol Metab (2012) 3.45

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care (2006) 2.40

Insulin-associated weight gain in diabetes--causes, effects and coping strategies. Diabetes Obes Metab (2007) 2.24

Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care (1989) 2.17

Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet (1994) 1.99

Natural history of beta-cell function in type 1 diabetes. Diabetes (2005) 1.98

Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab (2013) 1.92

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care (2002) 1.91

Predictors of glycaemic control and hypoglycaemia in children and adolescents with type 1 diabetes from NSW and the ACT. Med J Aust (2002) 1.81

Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther (2002) 1.59

Temporal patterns in overweight and obesity in Type 1 diabetes. Diabet Med (2010) 1.56

Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care (2009) 1.52

Insulin omission in women with IDDM. Diabetes Care (1994) 1.51

Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes. Diabetes Care (1999) 1.37

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med (2004) 1.34

The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications (2011) 1.29

The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia (2006) 1.18

Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol (2003) 1.16

Hypoglycemia in type 1 diabetes. Diabetes (2010) 1.13

Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol (2000) 1.11

Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia (1997) 1.08

Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am (2010) 1.07

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism (2002) 1.06

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des (2001) 1.05

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism (1999) 1.01

Homologous islet amyloid polypeptide: effects on plasma levels of glucagon, insulin and glucose in the mouse. Diabetes Res Clin Pract (1992) 0.98

Effect of increasing duration of diabetes mellitus type 2 on glycated hemoglobin and insulin sensitivity. Indian J Clin Biochem (2006) 0.97

Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism (1996) 0.94

Duration of type I diabetes affects glucagon and glucose responses to insulin-induced hypoglycemia. West J Med (1984) 0.93

The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care (1996) 0.91

Anorexia following the intrahypothalamic administration of amylin. Brain Res (1991) 0.87

Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care (1995) 0.86

Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study. Diabetes Obes Metab (2010) 0.86

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes (2005) 0.85

Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc Health Risk Manag (2006) 0.82

Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther (2007) 0.82

Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med (2013) 0.81

The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabetes Obes Metab (2005) 0.79

Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1996) 0.77